Establishment Labs (NASDAQ:ESTA) Shares Gap Up – What’s Next?

Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) gapped up before the market opened on Thursday . The stock had previously closed at $36.06, but opened at $38.00. Establishment Labs shares last traded at $38.09, with a volume of 113,380 shares traded.

Analysts Set New Price Targets

Separately, Stephens restated an “overweight” rating and set a $52.00 price objective on shares of Establishment Labs in a research report on Thursday. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, Establishment Labs currently has an average rating of “Moderate Buy” and an average price target of $57.40.

Establishment Labs Trading Up 0.8 %

The company has a debt-to-equity ratio of 5.94, a current ratio of 3.62 and a quick ratio of 2.29. The business’s 50-day moving average price is $37.50 and its two-hundred day moving average price is $41.35. The company has a market capitalization of $1.20 billion, a price-to-earnings ratio of -16.62 and a beta of 1.12.

Establishment Labs (NASDAQ:ESTA) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.98) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.34). Establishment Labs had a negative net margin of 46.13% and a negative return on equity of 184.55%. The business had revenue of $44.51 million during the quarter, compared to analyst estimates of $44.45 million. Research analysts predict that Establishment Labs Holdings Inc. will post -2.41 earnings per share for the current year.

Institutional Investors Weigh In On Establishment Labs

Hedge funds and other institutional investors have recently made changes to their positions in the business. Barclays PLC raised its position in shares of Establishment Labs by 9,643.3% in the third quarter. Barclays PLC now owns 31,471 shares of the company’s stock valued at $1,362,000 after buying an additional 31,148 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Establishment Labs by 89.5% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 41,351 shares of the company’s stock valued at $1,789,000 after purchasing an additional 19,531 shares in the last quarter. Assenagon Asset Management S.A. acquired a new position in Establishment Labs during the fourth quarter valued at approximately $12,898,000. Vestal Point Capital LP acquired a new position in Establishment Labs during the third quarter valued at approximately $1,731,000. Finally, Bamco Inc. NY raised its position in Establishment Labs by 13.6% during the third quarter. Bamco Inc. NY now owns 489,386 shares of the company’s stock valued at $21,176,000 after purchasing an additional 58,611 shares in the last quarter. 72.91% of the stock is currently owned by institutional investors and hedge funds.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.